Tag: calprotectin

Visit BUHLMANN at AACC 2019

BÜHLMANN fCAL® ELISA, accurate, precise, efficient calprotectin testing Health Canada License: 80726 US:  BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use. Quantum Blue® platform offering rapid and quantitative results for fecal calprotectin, serum calprotectin, CRP, serum infliximab trough levels, and serum adalimumab trough levels (Additional trough level assays coming soon!) Health Canada Licenses: Quantum Blue®  fCAL: 83477, Quantum Blue® fCAL extended: 100161 US: Research Use Only. Not
Continue Reading

Experience with BUHLMANN fCAL turbo- SYNLAB

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 A Report of A. Suter* and Dr. C. Fuhrer** from SYNLAB *BMA HF/ Fachleiterin, **Head of Core Lab, FAMH Clinical Chemistry, NF hematology, microbiology and immunology; SYNLAB Suisse SA, Alpenquai 14, 6002 Lucerne, Switzerland
Continue Reading

BUHLMANN fCAL turbo Customer Testimonials

  View a compilation of twelve user testimonials from UK, Ireland, Switzerland and France that have been published so far for the BÜHLMANN fCAL® turbo. Find valuable highlights, perspectives, advice and details about the successful applications of this automated calprotectin assay from each laboratory.   Read Testimonials
Continue Reading

Educational Webinar- Calprotectin in the Diagnosis of Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important
Continue Reading

Interview: BUHLMANN fCAL ELISA in a Clinical Laboratory- Expert User Perspectives

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 In this Video You will Learn: Background information on calprotectin and it’s use in primary care Technical details of calprotectin testing in the laboratory Perspectives and general tips on the use of the BÜHLMANN fCAL® ELISA Contact our team and learn more about
Continue Reading

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

IBDoc® Citation: Wei, S. , Tung, C. et al.  Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553. DOI: https://doi.org/10.5217/ir.2018.00052 PMID: 30301339 Highlights from this Publication “96% of the patients were satisfied with the home test..." “71% of patients preferred the home test method monitor
Continue Reading

LabSense News Fall 2018 Edition

Continue Reading

IBDoc® Talk – Tips and Tricks Teleconference

Health Canada Licence: 98903, Device class: 3  BÜHLMANN IBDoc® is not available for sale in the US. IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. IBDoc® allows IBD patients convenient self-testing of fecal calprotectin. Teleconference Overview Goal of Discussion The goal was for Clinical Administrators and Clinical Users from
Continue Reading

Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease.

BÜHLMANN fCAL® ELISA Citation Pavlidis, P. et al., 2016, Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease, Scandinavian Journal of Gastroenterology.  PMID: 27400728  DOI: 10.1080/00365521.2016.1205128 Highlight from this Publication “The ΔFCAL could act as an ‘early warning’ to consider alternatives such as dose optimisation or another biologic with a different mode of action,
Continue Reading

Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.

BÜHLMANN fCAL® ELISA Citation Lasson, A. et al., 2014, Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of relapse: A prospective, randomized, controlled study, United European Gastroenterology Journal.  PMID: 25653861 DOI: 10.1177/2050640614560785 Highlight from this Publication “In patients with UC, FC-guided dosing of the patient’s 5-ASA agent showed significantly lower relapse rates than
Continue Reading